Revolo Biotherapeutics to Participate in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment
September 16, 2022 11:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior...
Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of ‘1104 in Eosinophilic Esophagitis
September 12, 2022 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior...
Revolo Biotherapeutics to Present at the Baird 2022 Global Healthcare Conference
September 08, 2022 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior...
Revolo Biotherapeutics Awarded Innovation Passport for ‘1805 in the United Kingdom for the Treatment of Moderate to Severe Rheumatoid Arthritis
July 14, 2022 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, July 14, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior...
Revolo Biotherapeutics Announces Presentations at Upcoming Medical Meetings
May 16, 2022 14:00 ET
|
Revolo Biotherapeutics
Presenting new data on ‘1104 in allergic disease at the American Thoracic Society International Conference in San Francisco on May 17 Delivering an oral presentation on resetting the immune system to...
Revolo Biotherapeutics to Lead Panel Discussion on the Future of Autoimmune Disease Treatment
May 10, 2022 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS, May 10, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term...
Revolo Biotherapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium
May 05, 2022 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior...
Revolo Biotherapeutics to Participate at SVB Leerink Biopharma Private Company Connect
March 24, 2022 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, March 24, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior...
Revolo Biotherapeutics To Present New Data at 2022 AAAAI Annual Meeting Demonstrating the Anti-inflammatory Effect of ‘1104 in Acute Respiratory Distress Syndrome
February 25, 2022 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior...
Revolo Biotherapeutics Receives MHRA Approval for Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in the United Kingdom
February 04, 2022 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior...